Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
National Cancer Institute (NCI)
MEI Pharma, Inc.
Nurix Therapeutics, Inc.
Janssen Research & Development, LLC
BeOne Medicines
Eli Lilly and Company
Hoffmann-La Roche
Hutchmed
National Institutes of Health Clinical Center (CC)
Schrödinger, Inc.
Mayo Clinic
AbbVie
Baylor College of Medicine
H. Lee Moffitt Cancer Center and Research Institute
Baylor College of Medicine
AbbVie
AbbVie
University of California, San Francisco
National Institutes of Health Clinical Center (CC)
Acerta Pharma BV
Umoja Biopharma
AbbVie
Ohio State University Comprehensive Cancer Center
Dana-Farber Cancer Institute
Baylor College of Medicine
City of Hope Medical Center
Iovance Biotherapeutics, Inc.
Ohio State University Comprehensive Cancer Center
Acerta Pharma BV
Aurigene Discovery Technologies Limited
University of California, San Diego
Fate Therapeutics
Carna Biosciences, Inc.
Lomond Therapeutics Holdings, Inc.
National Cancer Institute (NCI)
City of Hope Medical Center
Case Comprehensive Cancer Center
University of Pennsylvania
OHSU Knight Cancer Institute
Case Comprehensive Cancer Center
Incyte Corporation
University of California, San Diego
Regeneron Pharmaceuticals
Novartis
Mayo Clinic
Janssen Research & Development, LLC
City of Hope Medical Center
Accutar Biotechnology Inc
Sana Biotechnology
Dana-Farber Cancer Institute